drugset / Trial / NCT06478251
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2026-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NW-301D | Cell therapy | — | Intravenous |
| Subject | NW-301V | Cell therapy | — | Intravenous |
Indications
No indication recorded.